College Station, Texas
March 6, 2003

ProdiGene, Inc. today announced the appointment of Russell K. Burbank as CEO and President to replace Anthony G. Laos, who has stepped down from his roles as President and CEO and as a member of ProdiGene's Board of Directors. The company also announced today the appointment of Dr. John A. Howard as Vice President and Chief Technical Officer.

Mr. Burbank is a managing director of The Scotland Group, Inc., a professional turnaround organization, and brings extensive business experience to ProdiGene. During his career, which included positions with Dow Chemical Co., Envirotech Corp., and Diamond Shamrock Corp., he led business units engaged in environmentally sensitive processes and is directly familiar with regulatory permitting and compliance practices. He has also been recruited on numerous occasions by Boards of Directors of public and private companies to plan and implement early stage commercialization of emerging technologies. Mr. Burbank has a BS in Chemical Engineering from the University of California, Berkeley, and a Stanford MBA.

Dr. Howard is a founder of ProdiGene and has been a Director of the company since 1996. He is internationally recognized for his work in transgenic plant technologies and is an inventor on numerous patents that covers the company's proprietary technology. Prior to this appointment, Dr. Howard had been consulting to the company. In his new position, he will be responsible for the company's research, development and commercial scale-up of products, including TrypZean(TM), a protease enzyme used in cell culture and as an intermediary in the production of pharmaceuticals, that marks
the first time that commercial quantities of a recombinant protein have been produced from transgenic plants. He will also oversee the company's scale-up of aprotinin, a protease inhibitor used in cardiac surgery and wound healing, and clinical trials of vaccines which would be delivered by the company's patented oral vaccine platform. Dr. Howard has a PhD in Biochemistry from the University of California at Riverside.

ProdiGene, headquartered in College Station, Texas, is a private biotechnology company that is developing and manufacturing industrial and pharmaceutical proteins from its proprietary transgenic plant system. ProdiGene, as the first and only company to produce and market recombinant proteins from transgenic plants, is well positioned to capitalize on the opportunities in the large and expanding recombinant protein markets. The Company has collaborations with leading biotechnology and pharmaceutical companies.